Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)

Inclusion Criteria: * either completed participation to one of the following: CL3-78989-002 open-label extension, or X052130/CL3-78989-005 double-masked period or open-label period, or X052131/CL3-78989-006 double-masked period or open-label period, or currently benefiting from gevokizumab compassionate use after participation in gevokizumab uveitis studies * Male or female, age ≥18 (or legal age of majority in the country) at selection. * For subject with reproductive potential, a willingness to use highly effective contraceptive measures Exclusion Criteria: * Meeting criteria for discontinuation of any of gevokizumab uveitis previous study. * Infectious uveitis and masquerade syndrome * History of severe allergic or anaphylactic reaction to study drug administration during previous study or to gevokizumab or any of its excipient. * Currently active infectious disease. Other protocol-defined inclusion/exclusion criteria may apply